Tyloxapol/NN
inhibits/VBZ
NF-kappa/NN
B/NN
and/CC
cytokine/NN
release/NN
,/,
scavenges/VBZ
HOCI/NN
,/,
and/CC
reduces/VBZ
viscosity/NN
of/IN
cystic/JJ
fibrosis/NN
sputum/NN
./.

Cystic/JJ
fibrosis/NN
(/(
CF/NN
)/)
patients/NNS
develop/VB
progressive/JJ
cytokine-mediated/JJ
inflammatory/JJ
lung/NN
disease/NN
,/,
with/IN
abundant/JJ
production/NN
of/IN
thick/JJ
,/,
tenacious/JJ
,/,
protease-/NN
and/CC
oxidant-rich/JJ
purulent/JJ
airway/NN
secretions/NNS
that/WDT
are/VBP
difficult/JJ
to/TO
clear/VB
even/RB
with/IN
physiotherapy/NN
./.
=====
In/IN
the/DT
search/NN
for/IN
a/DT
potential/JJ
treatment/NN
,/,
we/PRP
have/VBP
tested/VBN
tyloxapol/NN
,/,
an/DT
alkylaryl/NN
polyether/JJ
alcohol/NN
polymer/NN
detergent/NN
previously/RB
used/VBN
as/IN
a/DT
mucolytic/JJ
agent/NN
in/IN
adult/JJ
chronic/JJ
bronchitis/NN
./.
=====
Tyloxapol/NN
inhibits/VBZ
activation/NN
of/IN
the/DT
transcription/NN
factor/NN
nuclear/JJ
factor-kappa/NN
B/NN
(/(
NK-kappa/NN
B/NN
)/)
,/,
reduces/VBZ
resting/VBG
secretion/NN
of/IN
the/DT
cytokine/NN
interleukin-8/NN
(/(
IL-8/NN
)/)
in/IN
cultured/VBN
human/JJ
monocytes/NNS
,/,
and/CC
inhibits/VBZ
lipopolysaccharide/NN
(/(
LPS/NN
)/)
-stimulated/JJ
release/NN
of/IN
tumor/NN
necrosis/NN
factor-alpha/NN
(/(
TNF-alpha/NN
)/)
,/,
IL-1/NN
beta/NN
,/,
IL-6/NN
,/,
IL-8/NN
,/,
granulocyte-macrophage/JJ
colony-stimulating/JJ
factor/NN
(/(
GM-CSF/NN
)/)
,/,
and/CC
the/DT
eiconsanoids/NNS
thromboxane/NN
A2/NN
and/CC
leukotriene/NN
B4/NN
(/(
LTB4/NN
)/)
./.
=====
We/PRP
have/VBP
previously/RB
shown/VBN
that/IN
tyloxapol/NN
is/VBZ
a/DT
potent/JJ
antioxidant/NN
for/IN
hydroxyl/NN
radicals/NNS
(/(
OH/NN
)/)
./.
=====
Tyloxapol/NN
(/(
0.05/CD
to/TO
0.1/CD
%/NN
wt/vol/NN
)/)
effectively/RB
scavenges/VBZ
the/DT
oxidant/JJ
hypochlorous/JJ
acid/NN
(/(
HOCl/NN
;/:
1/CD
to/TO
7.5/CD
mM/NN
)/)
in/FW
vitro/FW
,/,
and/CC
protects/VBZ
from/IN
HOCl-mediated/JJ
lung/NN
injury/NN
in/IN
rats/NNS
./.
=====
Tyloxapol/NN
also/RB
reduces/VBZ
the/DT
viscosity/NN
of/IN
CF/NN
sputum/NN
(/(
from/IN
463/CD
+/-/CC
133/CD
to/TO
128/CD
+/-/CC
52/CD
centipoise/NN
)/)
./.
=====
We/PRP
conclude/VBP
that/IN
tyloxapol/NN
is/VBZ
potentially/RB
useful/JJ
as/IN
a/DT
new/JJ
antiinflammatory/JJ
therapy/NN
for/IN
CF/NN
lung/NN
disease/NN
,/,
and/CC
could/MD
possibly/RB
promote/VB
clearance/NN
of/IN
secretions/NNS
in/IN
the/DT
CF/NN
airway/NN
./.